South Korea · Delayed Price · Currency is KRW BL Pharmtech Statistics
Total Valuation
BL Pharmtech has a market cap or net worth of KRW 75.91 billion. The enterprise value is 73.60 billion.
| Market Cap | 75.91B |
| Enterprise Value | 73.60B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BL Pharmtech has 27.91 million shares outstanding. The number of shares has increased by 12.01% in one year.
| Current Share Class | 27.91M |
| Shares Outstanding | 27.91M |
| Shares Change (YoY) | +12.01% |
| Shares Change (QoQ) | -1.48% |
| Owned by Insiders (%) | 26.89% |
| Owned by Institutions (%) | n/a |
| Float | 20.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 24.57 |
| PB Ratio | 9.09 |
| P/TBV Ratio | 9.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 23.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.95, with a Debt / Equity ratio of 0.41.
| Current Ratio | 0.95 |
| Quick Ratio | 0.89 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.57 |
| Interest Coverage | -2.00 |
Financial Efficiency
Return on equity (ROE) is -103.82% and return on invested capital (ROIC) is -18.26%.
| Return on Equity (ROE) | -103.82% |
| Return on Assets (ROA) | -2.92% |
| Return on Invested Capital (ROIC) | -18.26% |
| Return on Capital Employed (ROCE) | -12.55% |
| Weighted Average Cost of Capital (WACC) | 17.52% |
| Revenue Per Employee | 257.50M |
| Profits Per Employee | -1.33B |
| Employee Count | 12 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 3.58 |
Taxes
In the past 12 months, BL Pharmtech has paid 30.62 million in taxes.
| Income Tax | 30.62M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +280.42% in the last 52 weeks. The beta is 2.44, so BL Pharmtech's price volatility has been higher than the market average.
| Beta (5Y) | 2.44 |
| 52-Week Price Change | +280.42% |
| 50-Day Moving Average | 2,540.08 |
| 200-Day Moving Average | 2,285.42 |
| Relative Strength Index (RSI) | 61.42 |
| Average Volume (20 Days) | 1,034,844 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BL Pharmtech had revenue of KRW 3.09 billion and -16.00 billion in losses. Loss per share was -598.61.
| Revenue | 3.09B |
| Gross Profit | 1.15B |
| Operating Income | -1.21B |
| Pretax Income | -15.98B |
| Net Income | -16.00B |
| EBITDA | -776.50M |
| EBIT | -1.21B |
| Loss Per Share | -598.61 |
Balance Sheet
The company has 5.79 billion in cash and 3.45 billion in debt, with a net cash position of 2.34 billion or 83.77 per share.
| Cash & Cash Equivalents | 5.79B |
| Total Debt | 3.45B |
| Net Cash | 2.34B |
| Net Cash Per Share | 83.77 |
| Equity (Book Value) | 8.35B |
| Book Value Per Share | 311.10 |
| Working Capital | -380.53M |
Cash Flow
| Operating Cash Flow | -1.34B |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 428.93M |
| Net Borrowing | -3.06B |
| Free Cash Flow | -1.34B |
| FCF Per Share | -48.11 |
Margins
| Gross Margin | 37.09% |
| Operating Margin | -39.01% |
| Pretax Margin | -517.15% |
| Profit Margin | n/a |
| EBITDA Margin | -25.13% |
| EBIT Margin | -39.01% |
| FCF Margin | n/a |
Dividends & Yields
BL Pharmtech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.01% |
| Shareholder Yield | -12.01% |
| Earnings Yield | -21.08% |
| FCF Yield | -1.77% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 26, 2025. It was a forward split with a ratio of 3.
| Last Split Date | Feb 26, 2025 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
BL Pharmtech has an Altman Z-Score of -5.29 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.29 |
| Piotroski F-Score | 2 |